Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.39 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.39 |
| ▸ | FGFR3 | P22607 | 3/20 | 0.39 |
| ▸ | KDR | P35968 | 2/20 | 0.39 |
| ▸ | FGFR4 | P22455 | 5/20 | 0.39 |
| ▸ | IGF1R | P08069 | 1/20 | 0.38 |
| ▸ | VNN1 | O95497 | 1/20 | 0.38 |
| ▸ | MAT2A | P31153 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CCND3 | P30281 | 1/20 | 0.37 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16176700 | 0.82 | FGFR4 (0.57) | FGFR1FGFR2FGFR3KDRFGFR4 | |
| SCHEMBL1521384 | 0.81 | FGFR1 (0.37) | FGFR1FGFR2FGFR3KDRFGFR4 | |
| SCHEMBL1521503 | 0.77 | FGFR4 (0.39) | FGFR1FGFR2FGFR3KDRFGFR4 | |
| SCHEMBL1521677 | 0.75 | FGFR1 (0.38) | FGFR1FGFR2FGFR3KDRFGFR4 | |
| SCHEMBL1521768 | 0.71 | FGFR1 (0.42) | FGFR1FGFR2FGFR3FGFR4 | |
| SCHEMBL1521618 | 0.69 | FGFR1 (0.39) | FGFR1FGFR2FGFR3FGFR4CDK6 | |
| SCHEMBL1521567 | 0.68 | FGFR4 (0.47) | HRH4FGFR1FGFR2FGFR3KDR | |
| SCHEMBL25766056 | 0.67 | MAPT (0.42) | HRH4HDAC1NPC1RAB9AKMT2A | |
| SCHEMBL1521532 | 0.67 | FGFR4 (0.50) | FGFR4 | |
| SCHEMBL4425301 | 0.67 | SRC (0.56) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110118271-A1 | Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases | FLYNN DANIEL L | 2011-05-19 | — | — | US | disclosed |
| US-7897762-B2 | Kinase inhibitors useful for the treatment of proliferative diseases | DECIPHERA PHARMACEUTICALS, LLC (US) | 2011-03-01 | — | — | US | disclosed |
| US-20090099190-A1 | Kinase inhibitors useful for the treatment of proliferative diseases | DECIPHERA PHARMACEUTICALS, LLC (US) | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118271-A1 | Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases | BRAF, PRKDC, RAF1 | HRH4 1905/4885HDAC1 1931/4885FGFR1 577/4885 |
| US-20090099190-A1 | Kinase inhibitors useful for the treatment of proliferative diseases | BRAF, PRKDC, RAF1 | HRH4 1905/4885HDAC1 1931/4885FGFR1 577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.